chemotherapy was based on intraoperative tumor description and clinical factors in line with current guidelines. We extrapolated results to TURBT cases performed for fee-for-service Medicare beneficiaries in 2016. Cost estimates were calculated as if all potential doses of MMC were replaced by gemcitabine across a variety of utilization rates (i.e., actual use, all indicated cases (ideal use), and actual plus ideal (increased use)). We used 2016 Medicare average sales price for typical doses of MMC ($1,152.61) and gemcitabine ($64.99). We used recent real-world estimates of 5% of TURBT cases for Medicare beneficiaries receiving intravesical chemotherapy.
INTRODUCTION AND OBJECTIVES: Previous studies in non-
urologic populations have demonstrated readmission to non-index hospitals can result in increased costs of care, and are a source of variation that can be targeted to decrease costs. However, this has not been well studied in urologic surgery populations. Therefore, our objective was to compare the cost of index vs. non-index readmissions following major urologic oncology surgeries.
METHODS: Patients undergoing radical cystectomy (RC), prostatectomy (RP), nephrectomy (RN), and partial nephrectomy (PN) for urologic cancers were identified between 2010-2014 in the Nationwide Readmissions Database. Among patients who experienced readmission within the 90-day post-operative period, the cost of first readmission was compared between readmissions to index vs. nonindex hospitals. Multivariable models controlling for patient, surgery, and hospital-level characteristics were used to determine if non-index readmission was associated with increased readmission costs.
RESULTS: Following major urologic oncology surgeries, 90-day readmission rates were 40.3% (RC, n[9,964), 5.8% (RP, n[12, 341), 14.9% (RN, n[11, 543) , 14.0% (PN, n[6, 419) , and 17.6% (NU, n[2,431). The percentages of readmitted patients with readmission to non-index hospitals were 26.6% (RC), 30.7% (RP), 28.7%(RN), 25.6% (PN), and 30.3% (NU). On multivariable modeling, non-index hospital readmissions were more expensive following RP ($10,826 vs. $9,585, p<0.001), but less expensive following radical cystectomy ($12,275 vs. $14,543, p[0.001) . The cost of index vs. non-index hospital readmissions was comparable following RN, PN, and NU ( Figure) .
CONCLUSIONS: Hospital readmission to non-index hospitals is a source of significant cost variability following RC and RP. Nonindex readmissions were more expensive than index readmissions following RP, but the opposite was true for RC. This suggests a unique approach must be used for each surgery to understand how to improve readmission costs. As there is increased focus on cost containment with the implementation of bundled payment models, there is a need to better understand the factors associated with cost variability based on hospital readmission location following RC and RP.
Source of Funding: None

MP29-05 OUTCOMES OF A PROTOCOL-BASED VIRTUAL STONE (TELEPHONE-BASED, NURSE LED) CLINIC FOR ONGOING SURVEILLANCE OF PATIENTS WITH KIDNEY STONES: 5-YEAR PROSPECTIVE ANALYSIS FROM AN ENDOUROLOGY CENTRE
Matt Archer, Amelia Pietropaolo, Davis Tanya, Sarah Prattley*, Bhaskar Somani, Southampton, United Kingdom INTRODUCTION AND OBJECTIVES: Patients with kidney stones often need on-going follow-up and imaging surveillance adding to the clinical burden and cost of treatment. This is usually done in face-to-face clinical appointments. However, this can be avoided in suitably counselled patients who can have a telephone-based nurse led follow-up instead. We look at the outcomes of stone patients from our protocol-based virtual stone follow-up clinic.
METHODS: Over a period of 5 years (2014) (2015) (2016) (2017) (2018) , all patients who were high risk of stone recurrence or with small asymptomatic stones were referred to our protocol-based nurse led virtual telephone stone clinic. The high-risk stone patient group included those with solitary kidneys, bilateral stones, those under 25 years of age, recurrent stone disease, uric acid and cystine stones. The follow-up duration and imaging were tailored and included a 6-or 12-months follow-up with either a plain KUB XR (radio-opaque stones) or USS
